November 21st 2024
In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.
November 13th 2024
PARP inhibitors: Treating mCRPC from a genetic basis
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
The promise of precision medicine for urologic cancers
December 8th 2020"As we slowly move toward the promise of precision medicine, it is important to understand fully this concept and the importance of testing and how it is to be used for diagnosis, management, and risk assessment," writes Raoul S. Concepcion, MD, FACS.
Androgen receptor inhibitors linked to increased fall and fracture risk in prostate cancer patients
December 2nd 2020“Further prospective studies are warranted to identify potential mechanisms and to develop strategies that include a fall risk assessment tool to examine the risk factors for falls or fracture,” the authors wrote.
Active surveillance data in prostate cancer show frequent upgrading, rare mortality
November 27th 2020"Despite some heterogeneity in the type and frequency of testing during the surveillance period, these results provide reassurance and increased confidence in the safe utilization of AS protocols for men with low-risk GG1, and selected GG2, prostate cancer," Mian writes.
Analysis supports using adjuvant over neoadjuvant ADT with RT for localized prostate cancer
November 25th 2020At a median follow-up of 15 years, the pooled analysis showed statistically significant improvements with adjuvant ADT over neoadjuvant ADT in biochemical failure, distant metastasis, and progression-free survival rates.
The current state of adjuvant radiotherapy post prostatectomy: 3 take-home messages
November 13th 2020"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.